Nabriva Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	36.94	28.9	5.03	9.48	9.66	5.32	6.48	3.77	2.4	28.8
Revenue Growth (YoY)	27.82%	474.80%	-46.98%	-1.81%	81.54%	-17.94%	72.07%	57.09%	-91.67%	-
Cost of Revenue	28.58	13.15	0.77	0.07	0	0	0	0	0	0
Gross Profit	8.35	15.75	4.26	9.41	9.66	5.32	6.48	3.77	2.4	28.8
Selling, General & Admin	45.26	51.65	55.29	62.49	41.74	29.47	13.54	7.92	3.74	3.16
Research & Development	14.26	12.63	15.1	26.42	82.29	49.62	47.99	23.6	9.36	8.06
Other Operating Expenses	4.32	0	0	0	0	0	0	0	0	-0.19
Operating Expenses	63.84	64.28	70.39	88.9	124.03	79.09	61.53	31.53	13.09	11.02
Operating Income	-55.49	-48.53	-66.13	-79.49	-114.38	-73.77	-55.05	-27.76	-10.7	17.78
Interest Expense / Income	0.7	0.9	1.65	3.39	0.13	0.04	0.08	22.09	2.91	9.02
Other Expense / Income	-0.57	-0.47	1.57	-0.22	0.22	-0.81	0.44	-2.44	0.52	-4.43
Pretax Income	-55.62	-48.96	-69.35	-82.66	-114.73	-73	-55.56	-47.41	-14.13	13.18
Income Tax	1.57	0.49	0.14	0.1	0.05	1.36	-0.67	-0.45	0.09	0.85
Net Income	-57.19	-49.45	-69.48	-82.76	-114.78	-74.36	-54.89	-46.96	-14.22	12.33
Shares Outstanding (Basic)	3	2	1	0	0	0	0	0	0	-
Shares Outstanding (Diluted)	3	2	1	0	0	0	0	0	0	-
Shares Change	54.67%	237.48%	73.12%	46.07%	70.28%	38.89%	102.93%	3159.12%	-	-
EPS (Basic)	-2.13	-2.85	-13.52	-27.88	-56.50	-62.25	-64.00	-120.00	-1109.75	949.58
EPS (Diluted)	-2.13	-2.85	-13.52	-27.88	-56.50	-62.25	-64.00	-120.00	-1109.75	766.98
Free Cash Flow	-36.92	-59.58	-71.44	-71.95	-72.95	-70.52	-48.93	-22.07	-11.49	-4.15
Free Cash Flow Per Share	-1.38	-3.44	-13.90	-24.24	-35.91	-59.10	-56.95	-52.14	-884.96	-
Gross Margin	22.62%	54.50%	84.76%	99.26%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-150.24%	-167.95%	-1315.42%	-838.40%	-1184.50%	-1386.88%	-849.23%	-736.87%	-446.04%	61.72%
Profit Margin	-154.83%	-171.14%	-1382.22%	-872.95%	-1188.69%	-1397.93%	-846.81%	-1246.72%	-593.08%	42.82%
Free Cash Flow Margin	-99.96%	-206.20%	-1421.21%	-758.92%	-755.51%	-1325.79%	-754.83%	-585.98%	-479.32%	-14.41%
Effective Tax Rate	-	-	-	-	-	-	-	-	-	6.47%
EBITDA	-54.7	-47.42	-66.88	-78.88	-114.09	-72.53	-55.25	-25.16	-11.05	22.36
EBITDA Margin	-148.10%	-164.12%	-1330.34%	-831.96%	-1181.52%	-1363.53%	-852.42%	-668.01%	-460.88%	77.64%
Depreciation & Amortization	0.22	0.64	0.82	0.4	0.51	0.43	0.23	0.15	0.17	0.16
EBIT	-54.92	-48.06	-67.7	-79.27	-114.6	-72.96	-55.49	-25.32	-11.22	22.2
EBIT Margin	-148.69%	-166.32%	-1346.65%	-836.14%	-1186.81%	-1371.65%	-856.02%	-672.07%	-467.81%	77.10%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).